<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2d1 20170631//EN" "JATS-journalpublishing1.dtd">
      <JournalTitle>Cancer Case Reports</JournalTitle>
      <Volume-Issue>Volume 1; Issue 1</Volume-Issue>
      <ArticleType>Cancer Research</ArticleType>
      <ArticleTitle>MDA as A Bio-Marker for Benign Prostatic Hyperplasia in Pakistani Population</ArticleTitle>
      <Abstract>Background: Serum malondialdehyde (MDA) is a convenient in vivo index of lipid peroxidation. It is a non-invasive biomarker of oxidative stress. Reactive oxygen species (ROS) could activate some specific signaling pathways that contribute to tumor development by regulating cell proliferation, angiogenesis and metastasis processes. Current study was designed to determine MDA levels in Benign Prostatic Hyperplasia (BPH) as compared to normal control. The study was a Cross-sectional analytical study, which was conducted at Department of Urology, Department of Biochemistry __ampersandsign Molecular Biology Rawalpindi, National University of Science and Technology, Islamabad over a period of one year. Study included sixty eight samples. MDA levels were determined by ELISA (enzyme linked immuno sorbent assay) technique.&#13;
Results: We have compared mean value of MDA in BPH and control group, the difference was statistically significant (p=0.002). Conclusions: MDA may be used as bio-marker to determine progression of BPH. Moreover, it is required that additional studies should be carried out to find the pathway involved serum MDA in BPH.</Abstract>
      <Keywords>Benign prostatic hyperplasia (BPH); Malondialdehyde (MDA); Gleason scoring</Keywords>
        <Abstract>https://cancercasereports.com/ubijournal-v1copy/journals/abstract.php?article_id=6378&amp;title=MDA as A Bio-Marker for Benign Prostatic Hyperplasia in Pakistani Population</Abstract>
        <References>Arsova-Sarafinovska Z, Eken A, Matevska N, Erdem O, Sayal A, Savaser A, Banev S, Petrovski D, Dzikova S, Georgiev V, Sikole A. Increased oxidative/nitrosative stress and decreased antioxidant enzyme activities in prostate cancer. Clinical biochemistry 2009; 42(12): 1228-1235.&#13;
Dillioglugil MO, Mek?k H, Muezzinoglu B, Ozkan TA, Demir CG, Dillioglugil O. Blood and tissue nitric oxide and malondialdehyde are prognostic indicators of localized prostate cancer. International urology and nephrology 2012; 44(6): 1691-1696.&#13;
Dvoracek J. Adenocarcinoma of the prostate. Casopis lekaru ceskych 1998; 137(17): 515-521.&#13;
Guzel S, Kiziler L, Aydemir B, Alici B, Ataus S, Aksu A, Durak H. Association of Pb, Cd, and Se concentrations and oxidative damage-related markers in different grades of prostate carcinoma. Biological trace element research 2012; 145(1): 23-32.&#13;
Merendino RA, Salvo F, Saija A, Di Pasquale G, Tomaino A, Minciullo PL, Fraccica G, Gangemi S. Malondialdehyde in benign prostate hypertrophy: a useful marker?. Mediators of inflammation 2003; 12(2): 127-128.&#13;
Pande D, Negi R, Karki K, Dwivedi US, Khanna RS, Khanna HD. Simultaneous progression of oxidative stress, angiogenesis, and cell proliferation in prostate carcinoma. Urol Oncol: seminars and original investigations 2013; 31(8): 1561-1566).&#13;
Paschos A, Pandya R, Duivenvoorden WC, Pinthus JH. Oxidative stress in prostate cancer: changing research concepts towards a novel paradigm for prevention and therapeutics. Prostate cancer and prostatic diseases 2013; 16(3): 217.&#13;
Rebillard A, Lefeuvre-Orfila L, Gueritat J, Cillard J. Prostate cancer and physical activity: adaptive response to oxidative stress. Free radical biology and medicine 2013; 60: 115-124.&#13;
van Breemen RB, Sharifi R, Viana M, Pajkovic N, Zhu D, Yuan L, Yang Y, Bowen PE, Stacewicz-Sapuntzakis M. Antioxidant effects of lycopene in African American men with prostate cancer or benign prostate hyperplasia: a randomized, controlled trial. Cancer prevention research 2011; 4(5): 711-718.&#13;
Yossepowitch O, Pinchuk I, Gur U, Neumann A, Lichtenberg D, Baniel J. Advanced but not localized prostate cancer is associated with increased oxidative stress. The Journal of urology 2007; 178(4): 1238-1244.&#13;
Zhang L, Shao N, Yu Q, Hua L, Mi Y, Feng N. Association between p53 Pro72Arg polymorphism and prostate cancer risk: a meta-analysis. Journal of biomedical research 2011; 25(1): 25.&#13;
Zibzibadze M, Bochorishvili I, Ramishvili L, Managadze L, Kotrikadze N. Investigation of pro-and antioxidative systems’ changes in blood of patients with prostate tumours. Georgian medical news 2009; (169): 26-29.</References>